DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for inherited hemoglobinopathy — screening already-approved drugs against its 31-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInherited hemoglobinopathy maps to a 31-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for inherited hemoglobinopathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tripartite motif containing 21 (TRIM21) — TRIM21 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3-dimethylamino-propyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8Y58 · 1.6 Å · ligand 1-[10-(3-DIMETHYLAMINO-PROPYL)-10H-PHENOTHIAZIN-2-YL]-ETHANONE (PMZ). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts describe inherited hemoglobinopathies as a broad group of genetic diseases of haemoglobin, divided into thalassaemia syndromes and structural variants such as HbS, HbE and HbC. Clinical severity ranges from mild hypochromic anaemia to severe transfusion-dependent anaemia with multiorgan involvement. More than 90% of patients currently survive into adulthood, and optimally treated patients have a projected life span of 50 to 60 years. Stem-cell transplantation is described as the preferred treatment for severe thalassaemia, while supportive care consists of lifelong transfusions with iron chelation. For sickle-cell disease, the drugs listed are analgesics, antibiotics, ACE inhibitors and hydroxyurea. A 2024 abstract repeats that treatment uses transfusions, hydroxyurea preparations and infusion therapy, with splenectomy and stem cell allotransplantation reserved for severe patients.
No abstract in this set reports a clinical trial of drug repurposing for inherited hemoglobinopathy. The 2011 review mentions hydroxyurea as a symptomatic drug for sickle-cell disease but gives no efficacy data, no response rates and no survival comparisons. The 2024 abstracts mention hydroxyurea preparations without any quantitative outcome. The 2009 chapter on rare haemoglobin variants, including unstable haemoglobins and those with altered oxygen affinity, notes that most mutations are not associated with haematological or clinical abnormalities and escape detection; it provides no therapeutic data. The 2014 Korean single-institute study reports that haemoglobinopathy in children has been diagnosed more frequently with molecular testing but gives no prevalence figures or complication rates in the abstract. The 2023 case report on haemoglobin J Iran states that this variant alone causes no specific clinical signs, but combination with beta-thalassaemia or other haemoglobinopathies can cause diagnostic challenges; it offers no treatment information.
The 1969 article frames haemoglobinopathies as a model for understanding genetic interactions but contains no clinical results. The 2015 book description lists chapters on mutation spectrum, diagnostic methods and treatment strategies without presenting any data. Across all abstracts, there is no evidence for any repurposed drug improving outcomes in inherited hemoglobinopathy. The only drug mentioned repeatedly is hydroxyurea, and its use is described as symptomatic for sickle-cell disease, not curative and not quantified. No abstract addresses gene therapy, novel small molecules or drug repurposing screens.
What is missing from this literature is any controlled trial data on drug repurposing for inherited hemoglobinopathy. There are no randomised comparisons, no patient stratification by genotype or severity, and no long-term follow-up of hydroxyurea or any other agent beyond supportive use. Funding for such trials, a clear trial design with defined endpoints, and stratification of patients by specific haemoglobin mutation would be required before any drug could be assessed for repurposing in this disease group.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Deutsches Ärzteblatt international · 2011 · 230 citations
Hemoglobinopathies
AbstractBACKGROUND: Hemoglobinopathies are among the most common inherited diseases around the world. They have become much more common recently in northern and central Europe, including Germany, due to immigration. METHOD: Selective review of the literature with consideration of national guidelines. RESULTS: The hemoglobinopathies encompass all genetic diseases of hemoglobin. They fall into two main groups: thalassemia syndromes and structural hemoglobin variants (abnormal hemoglobins). α- and β-thalassemia are the main types of thalassemia; the main structural hemoglobin variants are HbS, HbE and HbC. There are many subtypes and combined types in each group. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Stem-cell transplantation is the preferred treatment for the severe forms of thalassemia. Supportive, rather than curative, treatment consists of periodic blood transfusions for life, combined with iron chelation. Drugs to treat the symptoms of sickle-cell disease include analgesics, antibiotics, ACE inhibitors and hydroxyurea. Blood transfusions should be given only when strictly indicated. More than 90% of patients currently survive into adulthood. Optimally treated patients have a projected life span of 50 to 60 years. CONCLUSION: Hemoglobinopathies are a public health issue in today's multiethnic German population. Adequate care of the affected patients requires a wide variety of diagnostic and therapeutic measures.
Cambridge University Press eBooks · 2009 · 3 citations
OTHER CLINICALLY IMPORTANT DISORDERS OF HEMOGLOBIN
AbstractThree chapters discuss rare inherited hemoglobinopathies including unstable hemoglobins, hemoglobins with altered oxygen affinity, hemoglobins easily oxidized, and a miscellaneous group of hemoglobin variants with interesting biological properties, some of which are clinically important. Acquired disorders of hemoglobin can arise from heme iron oxidation due to inherited abnormalities of hemoglobin-reducing enzymes or because of exposure to exogenous oxidizing agents. Rare hemoglobinopathies have taught us much about the struc24-87519-function relationships of hemoglobin. Hemoglobin mutants have provided the most comprehensive list of mutations of any system in human biology, creating a map for understanding mutation in other genetic loci. Globin gene mutations – these include nearly every class of mutation so far described – provided an early catalog of the possible mechanisms of genetic disease. An accounting of globin gene mutations in early 2008 listed 1,326 unique mutations (http://globin.cse.psu.edu/). Here, we discuss some rare hemoglobin mutations. As comparatively few globin residues are critical for maintaining the structural integrity and functional utility of the molecule, most hemoglobin mutations are not associated with hematological or clinical abnormalities and so escape detection. Some mutations, although not medically important, illustrate interesting biological and anthropological principles. Abnormal hemoglobins with high or low oxygen affinity, variants that have their heme iron oxidized to the ferric form causing methemoglobinemia (HbM), or hemoglobin variants that are unstable are abnormalities seen rarely by the general physician and infrequently encountered in the practice of hematology.
AbstractThe book, Inherited Hemoglobin Disorders, describes the genetic defects of hemoglobins, disease complications, and therapeutic strategies. This book has two distinct sections. The first theme includes seven chapters devoted to the types of hemoglobinopathies, mutation spectrum, diagnostic methods, and disease complications, and the second theme includes three chapters focusing on various treatment strategies. The content of the chapters presented in the book is guided by the knowledge and experience of the contributing authors. This book serves as an important resource and review to the researchers in the field of hemoglobinopathies.
Imsang soa hyeoraek jong-yang/Imsang soa hyeol'aeg jong'yang/Clinical pediatric hematology-oncology · 2014 · 1 citations · open access
A Clinical Study on Hereditary Hemoglobinopathy: a Single Institute Experience
AbstractBackground: Hemoglobinopathy is inherited anemia characterized by abnormal structure of one of the globin chains of the hemoglobin molecule and has been known to be rare in Korea. However, hemoglobinopathy in children has been reported more frequently than in past with the recent advancement of molecular testing. The purpose of this study was to investigate the clinical and laboratory findings, prevalence and complications of hemoglobinopathy of children.
Reporting two hemoglobin J Iran cases, molecular follow-up, or is it insignificant?
AbstractBackground: Hemoglobin J is one of the fast hemoglobin that has a more negative charge due to β77His→Asp substitution. Acquisition of this hemoglobin is not associated with any specific clinical sign, but the combination of this hemoglobinopathy with beta-thalassemia and other hemoglobinopathies can cause challenges. Case Presentation: In this article, two cases with hemoglobin J are introduced; the first patient for premarital testing and the other for his fatigue. The hemoglobin electrophoresis was done by Sebia capillary zone electrophoresis and Hb J as heterozygote and homozygote were determined. Conclusion: It must be noted that although this hemoglobinopathy is not related to any problem alone but could be confusing in combination with other hemoglobinopathies or thalassemia. In this paper, these two cases are introduced and an attempt was made to investigate the importance of molecular follow-up.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
HEMOGLOBINOPATHY
AbstractHemoglobinopathies are a group of severe hereditary blood diseases caused by a violation of the structure of hemoglobin or a decrease in the synthesis of one or more globin chains. The clinical picture is extremely varied. Common symptoms are hemolytic anemia, enlarged spleen, and bone damage. Diagnosis is carried out using peripheral blood smear microscopy, hemoglobin electrophoresis, and genetic studies. For treatment, transfusions of blood components, hydroxyurea preparations, and infusion therapy are used. In severe patients, splenectomy and stem cell allotransplantation are performed.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
HEMOGLOBINOPATHY
AbstractHemoglobinopathies are a group of severe hereditary blood diseases caused by a violation of the structure of hemoglobin or a decrease in the synthesis of one or more globin chains. The clinical picture is extremely varied. Common symptoms are hemolytic anemia, enlarged spleen, and bone damage. Diagnosis is carried out using peripheral blood smear microscopy, hemoglobin electrophoresis, and genetic studies. For treatment, transfusions of blood components, hydroxyurea preparations, and infusion therapy are used. In severe patients, splenectomy and stem cell allotransplantation are performed.
AbstractUnderstanding the mechanisms underlying these disorders elucidates a number of basic principles involved in genetic interactions; this article therefore forms a logical introduction to a new series on medical genetics. More specifically, the hemoglobinopathies are perhaps the best understood among the inherited diseases in terms of tracing expressed anomalies to alterations in the genetic code.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
